JP2019514925A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514925A5 JP2019514925A5 JP2018556411A JP2018556411A JP2019514925A5 JP 2019514925 A5 JP2019514925 A5 JP 2019514925A5 JP 2018556411 A JP2018556411 A JP 2018556411A JP 2018556411 A JP2018556411 A JP 2018556411A JP 2019514925 A5 JP2019514925 A5 JP 2019514925A5
- Authority
- JP
- Japan
- Prior art keywords
- mace
- composition according
- placebo
- compared
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- 239000000902 placebo Substances 0.000 claims 10
- 229940068196 placebo Drugs 0.000 claims 10
- 230000000250 revascularization Effects 0.000 claims 5
- 206010002388 Angina unstable Diseases 0.000 claims 4
- 208000007814 Unstable Angina Diseases 0.000 claims 4
- 230000003111 delayed effect Effects 0.000 claims 4
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 4
- 231100001160 nonlethal Toxicity 0.000 claims 4
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 2
- 230000001934 delay Effects 0.000 claims 2
- 229950011186 semaglutide Drugs 0.000 claims 2
- 108010060325 semaglutide Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 238000011866 long-term treatment Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16167458.5 | 2016-04-28 | ||
| EP16167458 | 2016-04-28 | ||
| EP16188262.6 | 2016-09-12 | ||
| EP16188262 | 2016-09-12 | ||
| PCT/EP2017/060160 WO2017186896A1 (en) | 2016-04-28 | 2017-04-28 | Semaglutide in cardiovascular conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514925A JP2019514925A (ja) | 2019-06-06 |
| JP2019514925A5 true JP2019514925A5 (enExample) | 2020-06-18 |
| JP7221694B2 JP7221694B2 (ja) | 2023-02-14 |
Family
ID=58668875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018556411A Active JP7221694B2 (ja) | 2016-04-28 | 2017-04-28 | 心血管状態におけるセマグルチド |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US12569543B2 (enExample) |
| EP (1) | EP3448416B1 (enExample) |
| JP (1) | JP7221694B2 (enExample) |
| KR (3) | KR102778218B1 (enExample) |
| CN (1) | CN109069589B (enExample) |
| AU (2) | AU2017256774B2 (enExample) |
| BR (1) | BR112018072020A2 (enExample) |
| CA (1) | CA3022535A1 (enExample) |
| CL (1) | CL2018003045A1 (enExample) |
| DK (1) | DK3448416T3 (enExample) |
| ES (1) | ES2928007T3 (enExample) |
| HR (1) | HRP20221150T1 (enExample) |
| HU (1) | HUE060040T2 (enExample) |
| IL (1) | IL262390B1 (enExample) |
| MA (1) | MA44762A (enExample) |
| MX (1) | MX2018012700A (enExample) |
| MY (1) | MY202967A (enExample) |
| PH (1) | PH12018502274B1 (enExample) |
| PL (1) | PL3448416T3 (enExample) |
| RS (1) | RS63630B1 (enExample) |
| RU (1) | RU2768283C2 (enExample) |
| SI (1) | SI3448416T1 (enExample) |
| WO (1) | WO2017186896A1 (enExample) |
| ZA (2) | ZA202507395B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3448416T3 (pl) | 2016-04-28 | 2022-11-07 | Novo Nordisk A/S | Semaglutyd w schorzeniach sercowo-naczyniowych |
| BR112020002804A2 (pt) | 2017-08-24 | 2020-07-28 | Novo Nordisk A/S | composição farmacêutica líquida, e, kit |
| MY206306A (en) * | 2018-10-26 | 2024-12-07 | Novo Nordisk As | Stable semaglutide compositions and uses thereof |
| CN113194929B (zh) * | 2018-12-21 | 2022-12-09 | 诺和诺德股份有限公司 | Glp-1肽的喷雾干燥工艺 |
| IL294521A (en) * | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
| CN114699510B (zh) * | 2021-12-29 | 2024-07-16 | 浙江湃肽生物有限公司 | 一种司美格鲁肽微针阵列及其制备方法 |
| AU2023285400A1 (en) * | 2022-06-08 | 2024-12-05 | Zydus Lifesciences Limited | Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management |
| CN117462654A (zh) * | 2023-09-28 | 2024-01-30 | 武汉大学人民医院（湖北省人民医院） | 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用 |
| US20260199436A1 (en) * | 2025-01-16 | 2026-07-16 | Novo Nordisk A/S | Semaglutide in medical therapy including weight management |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2298378T3 (es) * | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | Formulacion estable de glp-1 modificado. |
| EP1494704A1 (en) * | 2002-04-04 | 2005-01-12 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
| KR101243648B1 (ko) | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| CN107028924A (zh) | 2009-10-02 | 2017-08-11 | 勃林格殷格翰国际有限公司 | 包含bi‑1356和二甲双胍的药物组合物 |
| EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
| MX341025B (es) * | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
| PH12012502524A1 (en) | 2010-06-24 | 2014-02-10 | Boehringer Ingelheim Int | Diabetes therapy |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| MX377589B (es) * | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| JP6126097B2 (ja) | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体 |
| US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| EP2854812A1 (en) | 2012-05-24 | 2015-04-08 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada |
| US20150290294A1 (en) | 2012-11-02 | 2015-10-15 | Mansoor Husain | Methods for inhibiting platelet aggregation using glp-1 receptor agonists |
| WO2014124860A1 (en) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Specific pde4b-inhibitors for the treatment of diabetes mellitus |
| JP2016510795A (ja) | 2013-03-15 | 2016-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
| WO2015071355A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| CN107613986A (zh) | 2015-04-07 | 2018-01-19 | 英特塞普特医药品公司 | 用于组合疗法的药物组合物 |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| PL3448416T3 (pl) * | 2016-04-28 | 2022-11-07 | Novo Nordisk A/S | Semaglutyd w schorzeniach sercowo-naczyniowych |
-
2017
- 2017-04-28 PL PL17721109.1T patent/PL3448416T3/pl unknown
- 2017-04-28 KR KR1020227036550A patent/KR102778218B1/ko active Active
- 2017-04-28 BR BR112018072020-8A patent/BR112018072020A2/pt not_active Application Discontinuation
- 2017-04-28 HR HRP20221150TT patent/HRP20221150T1/hr unknown
- 2017-04-28 EP EP17721109.1A patent/EP3448416B1/en active Active
- 2017-04-28 AU AU2017256774A patent/AU2017256774B2/en active Active
- 2017-04-28 PH PH1/2018/502274A patent/PH12018502274B1/en unknown
- 2017-04-28 KR KR1020257007151A patent/KR20250038818A/ko active Pending
- 2017-04-28 MX MX2018012700A patent/MX2018012700A/es unknown
- 2017-04-28 RU RU2018140900A patent/RU2768283C2/ru active
- 2017-04-28 RS RS20220901A patent/RS63630B1/sr unknown
- 2017-04-28 DK DK17721109.1T patent/DK3448416T3/da active
- 2017-04-28 SI SI201731219T patent/SI3448416T1/sl unknown
- 2017-04-28 HU HUE17721109A patent/HUE060040T2/hu unknown
- 2017-04-28 MA MA044762A patent/MA44762A/fr unknown
- 2017-04-28 ES ES17721109T patent/ES2928007T3/es active Active
- 2017-04-28 WO PCT/EP2017/060160 patent/WO2017186896A1/en not_active Ceased
- 2017-04-28 US US16/097,032 patent/US12569543B2/en active Active
- 2017-04-28 CA CA3022535A patent/CA3022535A1/en active Pending
- 2017-04-28 JP JP2018556411A patent/JP7221694B2/ja active Active
- 2017-04-28 CN CN201780026303.2A patent/CN109069589B/zh active Active
- 2017-04-28 KR KR1020187033310A patent/KR20180135012A/ko not_active Ceased
- 2017-04-28 MY MYPI2018703725A patent/MY202967A/en unknown
-
2018
- 2018-10-15 IL IL262390A patent/IL262390B1/en unknown
- 2018-10-25 CL CL2018003045A patent/CL2018003045A1/es unknown
-
2024
- 2024-10-04 AU AU2024227113A patent/AU2024227113A1/en active Pending
-
2025
- 2025-01-15 US US19/023,039 patent/US20250288649A1/en active Pending
- 2025-05-02 US US19/197,677 patent/US20250262281A1/en active Pending
- 2025-09-03 ZA ZA2025/07395A patent/ZA202507395B/en unknown
- 2025-09-03 ZA ZA2025/07394A patent/ZA202507394B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abraldes et al. | Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis | |
| RU2018140900A (ru) | Семаглутид при сердечно-сосудистых состояниях | |
| JP2018193377A5 (enExample) | ||
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| HRP20200445T1 (hr) | Metode liječenja ili prevencije tromboze u stentu | |
| Huddleston et al. | Emerging strategies for treating gout | |
| WO2015034678A3 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| JP2019533715A5 (enExample) | ||
| JP2017529830A5 (enExample) | ||
| MX380070B (es) | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. | |
| JP2021535175A5 (enExample) | ||
| JP2016510747A5 (enExample) | ||
| JP2015531749A5 (enExample) | ||
| JP2020531539A5 (enExample) | ||
| Nelson et al. | Aspirin: latest evidence and developments | |
| RU2017129068A (ru) | Способ лечения или профилактики атеротромботических явлений у пациентов с инфарктом миокарда в анамнезе | |
| Ganjehei et al. | Aspirin dosing in cardiovascular disease prevention and management: an update | |
| JP2020502134A5 (enExample) | ||
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
| Lenz et al. | Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke | |
| JP2020531537A5 (enExample) | ||
| JP2019507174A5 (enExample) | ||
| Garcia et al. | Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency | |
| CN104703602A (zh) | 1-金刚烷乙氧基-3-吗啉基-2-丙醇或其药学上可接受的盐的药物组合物用于治疗心血管病变 | |
| VerNooy et al. | Antiarrhythmic drug therapy of atrial fibrillation |